The widely used antimicrobial triclosan induces high levels of antibiotic tolerance in vitro and reduces antibiotic efficacy up to 100-fold in vivo by Westfall, Corey et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2019
The widely used antimicrobial triclosan induces
high levels of antibiotic tolerance in vitro and
reduces antibiotic efficacy up to 100-fold in vivo
Corey Westfall
Washington University in St. Louis
Ana Lidia Flores-Mireles
Washington University School of Medicine in St. Louis
John Isaac Robinson
Washington University School of Medicine in St. Louis
Aaron J.L. Lynch
Washington University School of Medicine in St. Louis
Scott Hultgren
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Westfall, Corey; Flores-Mireles, Ana Lidia; Robinson, John Isaac; Lynch, Aaron J.L.; Hultgren, Scott; Henderson, Jeffrey P.; and Levin,
Petra Anne, ,"The widely used antimicrobial triclosan induces high levels of antibiotic tolerance in vitro and reduces antibiotic efficacy
up to 100-fold in vivo." Antimicrobial agents and chemotherapy.63,5. e02312-18. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7741
Authors
Corey Westfall, Ana Lidia Flores-Mireles, John Isaac Robinson, Aaron J.L. Lynch, Scott Hultgren, Jeffrey P.
Henderson, and Petra Anne Levin
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/7741
The Widely Used Antimicrobial Triclosan Induces High Levels
of Antibiotic Tolerance In Vitro and Reduces Antibiotic Efﬁcacy
up to 100-Fold In Vivo
Corey Westfall,a Ana Lidia Flores-Mireles,b,d John Isaac Robinson,c Aaron J. L. Lynch,b Scott Hultgren,b
Jeffrey P. Henderson,c Petra Anne Levina
aDepartment of Biology, Washington University in St. Louis, St. Louis, Missouri, USA
bDepartment of Molecular Microbiology and Microbial Pathogenesis, Washington University School of Medicine, St. Louis, Missouri, USA
cDivision of Infectious Diseases, John T. Milliken Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
dDepartment of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA
ABSTRACT The antimicrobial triclosan is used in a wide range of consumer prod-
ucts ranging from toothpaste, cleansers, socks, and baby toys. A bacteriostatic inhib-
itor of fatty acid synthesis, triclosan is extremely stable and accumulates in the envi-
ronment. Approximately 75% of adults in the United States have detectable levels of
the compound in their urine, with a sizeable fraction of individuals (10%) having
urine concentrations equal to or greater than the minimal inhibitory concentration
for Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA). Previous
work has identiﬁed connections between defects in fatty acid synthesis and accumu-
lation of the alarmone guanosine tetraphosphate (ppGpp), which has been repeat-
edly associated with antibiotic tolerance and persistence. Based on these data, we
hypothesized that triclosan exposure may inadvertently drive bacteria into a state in
which they are able to tolerate normally lethal concentrations of antibiotics. Here we
report that clinically relevant concentrations of triclosan increased E. coli and MRSA
tolerance to bactericidal antibiotics as much as 10,000-fold in vitro and reduced anti-
biotic efﬁcacy up to 100-fold in a mouse urinary tract infection model. Genetic anal-
ysis indicated that triclosan-mediated antibiotic tolerance requires ppGpp synthesis
but is independent of growth. These data highlight an unexpected and certainly un-
intended consequence of adding high concentrations of antimicrobials in consumer
products, supporting an urgent need to reevaluate the costs and beneﬁts of the
prophylactic use of triclosan and other bacteriostatic compounds.
KEYWORDS antimicrobial agents, antimicrobial safety, genetics, urinary tract
infection
The prophylactic use of antibiotics in consumer goods ranging from animal feed topersonal care products is widely believed to be a major contributor to the epidemic
increase in antibiotic-resistant pathogens (1–3). Prominent among these prophylactics
are triclosan and triclocarban, polychlorinated aromatic antimicrobials targeting fatty
acid synthesis. Triclosan in particular is found in a wide variety of consumer products,
including toothpaste, cleansers, socks, and baby toys (1). Although the U.S. Food and
Drug Administration effectively banned the use of triclosan in household soap in 2017,
as of this writing Canada and Australia, among other countries, have not elected to take
similar actions.
An inhibitor of enoyl-acyl carrier protein reductase (4) at low concentrations
(200 ng/ml for E. coli), triclosan is bacteriostatic, preventing cell growth but having
little effect on viability over the short term. At high concentrations (10 g/ml),
CitationWestfall C, Flores-Mireles AL,
Robinson JI, Lynch AJL, Hultgren S, Henderson
JP, Levin PA. 2019. The widely used
antimicrobial triclosan induces high levels of
antibiotic tolerance in vitro and reduces
antibiotic efﬁcacy up to 100-fold in vivo.
Antimicrob Agents Chemother 63:e02312-18.
https://doi.org/10.1128/AAC.02312-18.
Copyright © 2019 Westfall et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Petra Anne Levin,
plevin@wustl.edu.
C.W. and A.L.F-M. contributed equally to this
study.
Received 31 October 2018
Returned for modiﬁcation 15 December
2018
Accepted 6 February 2019
Accepted manuscript posted online 19
February 2019
Published
MECHANISMS OF ACTION:
PHYSIOLOGICAL EFFECTS
crossm
May 2019 Volume 63 Issue 5 e02312-18 aac.asm.org 1Antimicrobial Agents and Chemotherapy
25 April 2019
 o
n
 M
ay 13, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
triclosan is bactericidal, most likely killing cells through disruption of plasma membrane
integrity (4). Recent work from the Waters lab suggests that at these higher concen-
trations triclosan can serve as an adjuvant, acting synergistically with tobramycin and
other drugs, increasing killing by100-fold in a Pseudomonas aeruginosa bioﬁlm model
for cystic ﬁbrosis lung infections (5). Triclosan is typically used as an antimicrobial
additive at these higher, bactericidal concentrations.
Because of its widespread use as a prophylactic, the high concentrations at which it
is employed, and its inherent stability, triclosan accumulates to high levels in the
environment (6, 7). Approximately 75% of adults in the United States have detectable
levels of the compound in their urine, and 10% have urine concentrations greater
than or equal to the MIC for Escherichia coli (200 ng/ml) and methicillin-resistant
Staphylococcus aureus (MRSA; 100 ng/ml) (8, 9).
While the inverse relationship between antibiotic use and antibiotic efﬁcacy is
largely attributable to the selection of heritable traits, nonheritable traits such as
antibiotic tolerance and persistence are also likely to be involved (10). In contrast to
genetically resistant bacteria, which grow in the presence of an antibiotic, tolerant
bacteria are able to survive antibiotic challenge for longer periods of time than their
more sensitive counterparts (10). Persister cells are the small subset of an otherwise-
sensitive population (1 in 106) that exhibit levels of tolerance sufﬁcient to protect
them from otherwise lethal concentrations of antimicrobial compounds (11). Increases
in antibiotic tolerance and persistence are confounding factors in the treatment of
chronic P. aeruginosa (12) and S. aureus (13) infections and are thought to contribute
to the refractory nature of medically relevant bioﬁlms (14). Reduced growth rate and
metabolic activity is associated with increased antibiotic tolerance (10) and is a deﬁning
trait of persister cells.
Based on previous work identifying connections between defects in fatty acid
synthesis and accumulation of the alarmone guanosine tetraphosphate (ppGpp) (15), as
well as reports of links between ppGpp and antibiotic tolerance (16, 17), we hypoth-
esized that triclosan exposure may inadvertently drive bacteria into a metabolically
depressed state in which they are able to tolerate normally lethal concentrations of
antibiotics (18, 19). In particular, inhibiting fatty acid synthesis stimulates interaction
between acyl carrier protein and the hydrolase domain of the bifunctional ppGpp
synthase SpoT, resulting in accumulation of the alarmone and the concomitant inhi-
bition of biosynthetic capacity (20).
Here we report that clinically relevant bacteriostatic concentrations of triclosan
increased E. coli and methicillin-resistant S. aureus (MRSA) tolerance to bactericidal
antibiotics as much as 10,00-fold in vitro and reduced antibiotic efﬁcacy 100-fold in
a mouse urinary tract infection (UTI) model. Triclosan-mediated antibiotic tolerance is
dependent on ppGpp synthesis: although triclosan inhibited the growth of both
wild-type and ppGpp mutant cells, only the latter were highly susceptible to challenge
with bactericidal compounds. In contrast, pretreatment with another bacteriostatic
drug, spectinomycin, a translation inhibitor that does not impact ppGpp accumulation
(21), induced high levels of antibiotic tolerance in both wild-type and ppGpp mutant
cells. Together, these data highlight an unexpected and certainly unintended conse-
quence of employing triclosan as a commercial antimicrobial and support an urgent
need to reevaluate the costs and beneﬁts of the addition of triclosan and potentially
other bacteriostatic compounds to consumer products.
RESULTS
Triclosan pretreatment results in high levels of tolerance to bactericidal anti-
biotics in vitro. To assess whether physiologically relevant levels of triclosan are
sufﬁcient to promote tolerance to bactericidal antibiotics, we examined the relative
sensitivity of E. coli (MG1655) and S. aureus (FPR3757 an USA-300 MRSA strain) cultured
in MICs of triclosan to a panel of bactericidal antibiotics. The triclosan MICs for E. coli
and MRSA were 200 and 100 ng/ml, respectively, under our growth conditions, similar
to the triclosan concentration found in the urine from individuals using triclosan-
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containing products (8, 9). In all cases, triclosan was added 30 min prior to the addition
of the speciﬁed bactericidal antibiotic, and both antibiotics were maintained in the
culture for the remainder of the experiment.
Triclosan had a dramatic protective effect on E. coli in an endpoint assay, increasing
survival by several orders of magnitude in the presence of three bactericidal antibiotics
and providing nearly complete protection against a fourth (Fig. 1). E. coli treated with
triclosan exhibited a 1,000-fold increase in survival in the presence of 50 g/ml (5
MIC) kanamycin, an inhibitor of peptide bond formation. Triclosan treated cells also
showed a 10,000-fold increase in survival in the presence of streptomycin (50 g/ml;
2 MIC), an inhibitor of tRNA-ribosome interaction, and ciproﬂoxacin (100 ng/ml;
3 MIC), a gyrase inhibitor (Fig. 1). Strikingly, triclosan rendered E. coli almost
completely refractory to treatment with the cell wall active antibiotic ampicillin
(100 g/ml; 10 MIC). Viable cell numbers were essentially identical in triclosan-
treated and triclosan-ampicillin-treated cultures at 2 h, and 10% of cells in triclosan-
ampicillin cultures were viable at 20 h, suggesting that triclosan increased persister
frequency to all tested antibiotics.
Triclosan also protected MRSA cells from high concentrations of the glycopeptide
antibiotic, vancomycin, over the course of a 20-h experiment (Fig. 2C). MRSA treated
FIG 1 Triclosan induces tolerance to multiple antibiotics. E. coli (MG1655) were cultured to an
OD600 of 0.2, split, and cultured for an additional 30 min with (T) or without (–T) 200 ng/ml triclosan.
The indicated bactericidal antibiotics were then added, and the cells were cultured for an additional 2
to 20 h prior to dilution plating. Each experiment was replicated three independent times, with only
representative data shown.
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with 100 ng/ml of triclosan were essentially refractory to 50 ng/ml vancomycin (10
MIC) at 4 h and exhibited a viable cell count 200 times that of untreated cells at 8 h.
The viable cell count, even at 20 h, was several times higher in the presence of both
triclosan and vancomycin than vancomycin alone. This delayed reduction in viable cell
count is consistent with induction of a persistent state (10).
Triclosan increases persister cell frequency. To further assess the protective effect
of triclosan, we performed kinetic kill curves, in which we measured the CFU over a 20-h
time frame. If persister cells are present, we expect to observe two slopes, one
corresponding to the kill rate of the general population and the second slope corre-
sponding to the slower kill rate of persister cells (10). In this manner, the kill curve is
able to separate antibiotic tolerance at the population level from the impact of triclosan
treatment on persister levels.
For these experiments, we focused on ciproﬂoxacin, the broad-spectrum antibiotic
used to treat E. coli-related UTIs. Consistent with the results of the endpoint assay (Fig.
1), triclosan substantially protected E. coli from ciproﬂoxacin-induced cell death
throughout the duration of the time course (Fig. 2a and b). Protection was particularly
pronounced at the 2-h time point, where the slope of the kill curve for pretreated cells
diverged substantially from that of untreated cells (Fig. 2A). A reduced kill rate suggests
that the pretreated population contains a larger proportion of persister cells (22).
In agreement with previous work (16), persister population size was proportional to
the concentration of ciproﬂoxacin. 10% of triclosan-treated MG1655 cells cultured in
100 ng/ml ciproﬂoxacin remained viable after 2 h (Fig. 2A), while only 0.1% cultured in
the more clinically relevant 1,000 ng/ml ciproﬂoxacin were viable at the same time
point (Fig. 2B). For perspective, 0.1% is 1,000-fold higher than the expected frequency
FIG 2 Kinetic analysis of triclosan-induced persistence. E. coli (MG1655) and MRSA (FPR3757) cells were cultured to an
OD600 of 0.2, split and cultured for an additional 30 min with (black line, closed squares) or without triclosan (gray line,
open squares). (A to C) At t 0, 100 ng/ml (A) or 1,000 ng/ml ciproﬂoxacin (B) was added to the E. coli cultures, and
50 ng/ml vancomycin was added to the MRSA cultures (C). (D) The relative persistence in the presence of triclosan
(CFUT/CFU–T) was calculated from the 4- and 20-h time points. Values are the means of three independent biological
replicates, with error bars representing the SEM. Asterisks represent signiﬁcant differences between triclosan-treated and
nontreated samples calculated using a Student two-tailed t test (*, P  0.05).
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of persisters in an untreated population (10). After 20 h, 90,000 CFU/ml were viable in
cultures treated with both triclosan and 100 ng/ml ciproﬂoxacin (Fig. 2A) compared to
20 cells/ml in cultures treated with ciproﬂoxacin alone. At 1,000 ng/ml ciproﬂoxacin,
cultures treated with both triclosan and ciproﬂoxacin contained 30 viable cells per ml
(Fig. 2B). In contrast, we were unable to detect viable cells (10 cells/ml) in cultures
treated with 1,000 ng/ml ciproﬂoxacin alone. We observed an increase in the abun-
dance of persisters at drug concentrations above 1,000 ng/ml (see Fig. S1 in the
supplemental material) (16). Although this ﬁnding initially appeared counterintuitive, it
is consistent with previous reports suggesting that prophage induction in response to
DNA damage is responsible for cell death at lower concentrations of ciproﬂoxacin,
while higher concentrations kill bacteria before prophage are induced (16).
Triclosan-mediated tolerance requires ppGpp. Based on the well-established
connection between defects in fatty acid synthesis and accumulation of ppGpp, we
speculated that triclosan mediated tolerance was dependent on synthesis of the
alarmone (15). To test this idea, we compared the relative viability of wild-type E. coli
to mutants unable to synthesize the alarmone (ppGpp0; spoT::cat ΔrelA) 2 h after
antibiotic challenge in the presence or absence of triclosan.
Although 200 ng/ml triclosan was sufﬁcient to inhibit the growth of both wild-type
and ppGpp0 cells, it was unable to substantially protect ppGpp0 cells from any of the
four bactericidal antibiotics we tested. These include ampicillin and ciproﬂoxacin, as
well as the translation inhibitors, kanamycin and streptomycin (Fig. 3A and B). The
ppGpp0 cells were more sensitive to kanamycin and streptomycin, showing no viable
cells after a 60-min treatment; thus, measurements were performed at 30 min. Impor-
tantly, triclosan alone was not bactericidal to either wild-type or ppGpp0 cells (Fig. S2).
In contrast to triclosan, pretreatment with another bacteriostatic compound, spec-
tinomycin, increased tolerance to kanamycin, streptomycin, ampicillin, and ciproﬂoxa-
cin in both wild-type and ppGpp0 mutant cells (Fig. 3C). A translation inhibitor,
spectinomycin, does not impact ppGpp levels in E. coli (21). Although spectinomycin
was still protective in the ppGpp0 cells, levels of protection were slightly decreased
compared to wild-type cells.
Triclosan drives tolerance to ciproﬂoxacin in a murine model. Due to its wide-
spread use and inherent stability, triclosan is present in both human populations and
the environment at concentrations high enough to inhibit bacterial growth (8). Thus, a
key question is whether the tolerance we observed in vitro is relevant in vivo. To
determine the physiological relevance of triclosan-mediated tolerance, we employed a
mouse model of E. coli UTI. UTIs are one of the most prevalent bacterial infections,
impacting approximately 150 million people annually (23). Uropathogenic E. coli is the
main causative agent of both uncomplicated and complicated UTI (24). Pretreatment
with triclosan rendered the well-characterized E. coli cystitis isolate UTI89 10-fold
more tolerant to 1,000 ng/ml ciproﬂoxacin than untreated cells at 2 h, a level equivalent
to the tolerance we observed for E. coli MG1655 at the same time point (Fig. 1 and
Fig. S3).
For in vivo experiments, we provided 6-week-old female wild-type C3H/HeN mice
with drinking water containing 1,000 ng/ml triclosan for 21 days. Control mice were
given plain water for the same duration. At 21 days, experimental and control mice
were transurethrally infected with 5 107 CFU of E. coli UTI89. At 24 h postinfection,
a subset of the mice was treated with intraperitoneal ciproﬂoxacin (25 mg/kg). At 48 h
postinfection, all mice were sacriﬁced, and bacterial colonization was assessed in the
urine and bladder.
After ciproﬂoxacin treatment, bacterial titers were 100-fold higher in the urine
(P 0.0001) and10-fold higher (P 0.0001) in the bladders of triclosan-treated mice
versus control animals (Fig. 4A and B), consistent with triclosan-induced tolerance
occurring in vivo. The bacterial load at 24 h postinfection was nearly equivalent in
triclosan-treated and control mice, indicating that triclosan did not signiﬁcantly impair
UTI89 viability (Fig. 4A and B). Treated mice had triclosan levels between 70 and
Triclosan Induces Antibiotic Tolerance Antimicrobial Agents and Chemotherapy
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750 ng/ml in their urine, a ﬁnding comparable to the MIC for E. coli (200 ng/ml) and
similar to reported triclosan levels in human urine (2.4 to 3,790 ng/ml) (8) (Fig. 4C). We
also detected two putative metabolized forms of triclosan, one with a mass consistent
with the previously reported sulfonated triclosan (25) and the other 96 Da larger (Fig.
S4). Whether or not the modiﬁed forms of the drug are active against bacteria is
unclear. Control mice had no observable triclosan (below 1.6 ng/ml limit of quantiﬁ-
cation).
DISCUSSION
Our data indicate that environmentally relevant concentrations of triclosan reduce
antibiotic efﬁcacy as much a 100-fold in vivo (Fig. 4) and highlight an unexpected and
potentially important role for triclosan as a contributor to antibiotic tolerance and
bacterial persistence in both community and health care settings. Triclosan-mediated
tolerance in E. coli is dependent on ppGpp synthesis, most likely in response to
FIG 3 ppGpp is needed for triclosan induced tolerance. (A) Cell viability of MG1655 and ppGpp0 E. coli with (T) or without (–T) pretreatment with triclosan
after challenge with antibiotic. (B) Growth curves of MG1655 (black curve) or ppGpp0 (gray curve) in LB with (dashed lines) or without (solid lines) triclosan.
(C) Cell viability of MG1655 and ppGpp0 E. coli with (T) or without (–T) pretreatment with spectinomycin after challenge with antibiotic. Values are means
of three independent biological replicates, with error bars representing the SEM. Asterisks represent signiﬁcant differences between triclosan-treated and
nontreated samples calculated using a Student two-tailed t test (*, P  0.05; **, P  0.001).
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inhibition of fatty acid synthesis (Fig. 3A) (15). This ﬁnding is consistent with prior work
implicating ppGpp in antibiotic tolerance and persister development (16).
In contrast to previous studies of ppGpp-induced persistence that relied on either
carbon starvation or the addition of serine hydroxamate to induce accumulation of
high concentrations of ppGpp (100 above baseline) (26, 27), defects in fatty acid
synthesis have at best a modest impact on ppGpp levels (5 over baseline) (15). This
suggests that even relatively low levels of ppGpp are sufﬁcient to protect cells from a
panel of antimicrobials. Speciﬁcally how modest increases in ppGpp might confer
tolerance to different antibiotics thus remains an open question.
Antibiotic persisters are generally divided into two categories: the trigger-induced
type I and the stochastic type II. Research on the type I persisters has generally focused
on entry into stationary phase as the triggering factor (10). Our data support triclosan
as a separate trigger, putting triclosan-induced persistence under the type I umbrella.
While previous work on both type I and II persisters identiﬁed links between growth
rate and persistence, it is unclear whether reductions in growth were causative or
merely correlative (10). We found that triclosan inhibits cell growth independent of
ppGpp production (Fig. 3B), while triclosan-mediated changes in antibiotic tolerance
and persistence require a functional ppGpp response (Fig. 3A). Together, these data
support a model in which persistence and tolerance are complex phenomena, likely
dependent on multiple growth-dependent and growth-independent factors.
FIG 4 Triclosan reduces ciproﬂoxacin efﬁcacy up to 100-fold in a mouse UTI model. For each round of the experiment, 15
mice were given water-containing triclosan (100 g/ml) for 21 days, and 15 control mice received plain water. At 21 days,
all mice were infected with E. coli UTI89 (5 107 CFU). At 24 h postinfection, 10 mice from each group were given
25 mg/kg of ciproﬂoxacin intraperitoneally. At 48 h postinfection, urine samples (A) were obtained, and then the mice were
sacriﬁced and bladders (B) were harvested. To compare the mice groups, Mann-Whitney U test was used, a P value of0.05
was considered statistically signiﬁcant (*, P  0.05; **, P  0.005; ***, P  0.0005; ns, values were not statistically different).
The horizontal bar represents the median value. The horizontal broken line represents the limit of detection of viable
bacteria. The data are from three independent experiments. (C) Free triclosan levels measured by LC-MS/MS of triclosan
in untreated and treated mouse urine. (A total of 45 mice were untreated, and 45 mice were treated; these mice were
divided into three independent experiments. Urine samples from three to four mice were pooled for triclosan analysis.) The
horizontal broken line represents the limit of quantiﬁcation of triclosan.
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We favor the idea that triclosan induces tolerance in wild-type cells primarily via its
indirect, positive impact on intracellular ppGpp levels and the concomitant downregu-
lation of global biosynthesis. Triclosan inhibits fatty acid synthesis, reducing activity of
the SpoT hydrolase and increasing intracellular ppGpp concentration (20). ppGpp in
turn inhibits ﬂux through multiple biosynthetic pathways, increasing tolerance to
cognate antimicrobials. For example, in this model ppGpp-dependent reductions in
DNA replication and protein synthesis reduce sensitivity to ciproﬂoxacin and kanamy-
cin, compounds that target DNA gyrase and the ribosome, respectively (28–30). While
triclosan inhibits fatty acid synthesis and restricts growth in wild-type and ppGpp0
mutants alike, DNA replication, translation, and cell wall synthesis likely remain at least
partially intact in the absence of ppGpp, rendering the mutants sensitive to antibiotics
targeting those pathways (31). In contrast, spectinomycin inhibits protein synthesis
directly, resulting in a general, ppGpp-independent downregulation of biosynthesis
and an increase in tolerance to drugs targeting downregulated processes, even in the
ppGpp0 cells (Fig. 3C).
In vivo, triclosan may also contribute to tolerance by promoting attachment and
bioﬁlm formation. Bacteria in bioﬁlms typically exhibit enhanced antibiotic tolerance, in
part due to their high cell density and reduced metabolic rate (32). Increases in ppGpp
concentration are associated with enhanced bioﬁlm formation in E. coli (33), and
triclosan has been shown to increase surface attachment and bioﬁlm formation in S.
aureus (34).
An open question is the impact of triclosan on tolerance in other bacterial systems.
Triclosan increases tolerance in S. aureus in vitro (Fig. 2C), although the dependence on
ppGpp remains an open question. While S. aureus can cause UTIs, it predominantly
infects the skin, where residual triclosan concentrations likely vary substantially and
quantiﬁcation is signiﬁcantly more challenging than urine (35). It is, however, worth
noting that studies of the nasal cavity have identiﬁed levels of triclosan high enough to
potentially induce tolerance (34).
Prescribing a bacteriostatic compound prior or along with delivery of a bactericidal
one is generally recognized as poor practice (36) due to the potential of the former
interfering with the activity of the other. At the same time, bacteriostatic mechanisms
of action, and thus the mechanisms by which these drugs drive tolerance are likely to
differ widely. While the translation inhibitor spectinomycin provides protection against
bactericidal compounds, it does not induce accumulation of ppGpp (21), a fact sup-
ported by our ﬁnding that spectinomycin induces tolerance to bactericidal compounds
in both wild-type and ppGpp0 cells (Fig. 3c). At the same time, ppGpp-dependent
induction of antibiotic tolerance is likely to be a feature triclosan shares with a related
compound, triclocarban, which similarly inhibits an early step in fatty acid synthesis and
is also a common additive in consumer products. Triclosan also stands out from other
bacteriostatic compounds by virtue of its widespread use and sheer abundance in the
environment. 1 kg of triclosan is produced for every 3 kg of other antimicrobials and
estimates indicate that 100 metric tons are being deposited annually in the environ-
ment through wastewater treatment in the United States alone (37).
Although triclosan has low toxicity (50% lethal dose  4,350 mg/kg orally) (38),
accumulating data link long-term exposure with antibiotic resistance (39), and there are
reports that triclosan may also function as an endocrine disrupter (40, 41). Our analysis
of the impact of triclosan on antibiotic efﬁcacy in a mouse UTI model (Fig. 4) highlights
yet another deleterious “side effect” of this ubiquitous antimicrobial. UTIs alone impact
150 million people worldwide (23) at a cost of $3.5 billion per year in the United States
alone (42). Complications associated with UTIs include pyelonephritis with sepsis, renal
damage, preterm birth, Clostridium difﬁcile colitis, sepsis, and death, particularly in the
very old and the very young (24). Coupled with the well-established connection
between antibiotic tolerance and recurrent/chronic infections (12, 13), our ﬁndings
reinforce the need for substantial caution—as well as consideration of unintended
consequences—in evaluating the costs and beneﬁts of antimicrobial additives in
consumer products.
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MATERIALS AND METHODS
Materials and strains. Triclosan, ampicillin, kanamycin, streptomycin, ciproﬂoxacin, and vancomycin
were purchased from Sigma-Aldrich. Stock solutions were made in water for ampicillin (100 mg/ml),
kanamycin (50 mg/ml), streptomycin (100 mg/ml), and ciproﬂoxacin (10 mg/ml). Triclosan was dissolved
in ethanol (10 mg/ml), and vancomycin was dissolved in dimethyl sulfoxide (100 mg/ml). E. coli MG1655
and S. aureus FPR3575 were both lab strains, and E. coli UTI89 was isolated from a patient with a UTI (43).
E. coli was grown in Luria-Bertani broth (LB), and S. aureus was grown in tryptic soy broth (TSB). Growth
temperature was 37°C for all experiments.
Determination of MIC (MIC). To determine the MIC for the panel of antibiotics utilized in this study,
E. coli and S. aureus were grown to optical density at 600 nm (OD600) of 0.1 in LB or TSB, respectively. Cells
were then back-diluted 1,000-fold and transferred to a 96-well plate containing 2-fold dilutions of
respective antibiotics and cultured at 37° for 16 additional hours with vigorous shaking in a BioTek Eon
plate reader. MIC was calculated as the lowest antibiotic concentration preventing development of
detectable turbidity at OD600.
Assays for antibiotic tolerance and persistence. To assay tolerance and persistence, E. coli and S.
aureus were grown to an OD600 of 0.2 in LB or TSB, respectively. Cells were then back-diluted to an
OD600 of 0.1 in medium containing triclosan at the indicated concentrations and cultured for an addi-
tional 30 min before being challenged with bactericidal antibiotics. For dot plating, 10 l of a 10-fold
dilution series was plated on antibiotic-free LB-agar or TSB-agar as appropriate. For determination of the
CFU, 100 l of a 10-fold dilution series was spread on antibiotic free LB-agar or TSB-agar plates. Cells were
incubated for 12 h at 37°C prior to quantiﬁcation. CFU were normalized to CFU at the initial time point
to correct for the 2-fold increase in cell number in untreated cultures during the 30 min pretreatment
period. The relative persistence is deﬁned as the CFU of the triclosan-treated sample divided by the CFU
of the nontreated sample.
UTI mouse work. Six-week-old female wild-type C3H/HeN mice were obtained from Envigo. Mice
were treated with or without 100 g/ml triclosan (100 ppm) in the drinking water for 21 days. At 21 days,
the mice were anesthetized by inhalation of 4% isoﬂurane, and mouse bladders were transurethrally
infected with approximately 5 107 CFU of E. coli UTI89 in 50 l of PBS (44). Brieﬂy, a single UTI89 colony
was inoculated in 20 ml of LB and incubated at 37°C under static conditions for 24 h. Bacteria were then
diluted (1:1,000) into fresh LB and incubated at 37°C under static conditions for 18 to 24 h. Bacteria were
subsequently washed three times with phosphate-buffered saline (PBS) and then concentrated to
approximately 5 107 CFU per 50 l. At 24 h postinfection, mice received 25 mg/kg of ciproﬂoxacin
intraperitoneal. At 48 h postinfection, mice were euthanized, bladders were harvested, and urine samples
were collected. Bladders were homogenized in PBS, and the bacterial load present in bladders and urine
samples was determined by plating serial dilutions on LB-agar supplemented with antibiotics when
appropriate. Statistical analyses were performed using a Mann-Whitney U test with GraphPad Prism
software (v6.0 for Mac). All animal studies were performed in accordance with the guidelines of the
Committee for Animal Studies at Washington University School of Medicine.
Measurement of triclosan and metabolites in mouse urine. Since triclosan has been observed to
adsorb to plastic surfaces, sample handling was performed in glass vessels whenever possible (25). A
stock solution of 1 mg/ml triclosan (Sigma) was prepared in methanol and a 100 g/ml 13C12-triclosan
(99%) internal standard in methyl tert-butyl ether was purchased from Cambridge Isotope Laboratories
(Andover, MA). A dilution series of 1,000, 200, 40, 8, 1.6, and 0.32 ng/ml triclosan was prepared in pooled,
untreated mouse urine and spiked with 100 ng/ml 13C12-triclosan internal standard. Samples were diluted
1:1 in methanol, spun down at 20,000 g for 10 min, and ﬁltered through 0.45-m-pore-size, 13-mm-
diameter polyvinylidene diﬂuoride syringe ﬁlters (Millipore). Finally, cleaned samples were diluted 1:1 in
high-pressure liquid chromatography-grade water (Sigma).
Using a Shimadzu UFLC (Kyoto, Japan), 10 l of each sample was injected onto a fused core
phenyl-hexyl column (100 mm 2 mm 2.7 m) with a 0.4 ml/min ﬂow rate (Ascentis Express; Supelco).
Triclosan was eluted from the column as follows: solvent A (0.1% formic acid) and solvent B (90%
acetonitrile with 0.1% formic acid) were held constant at 80 and 20%, respectively, for 0.1 min. Solvent
B was increased to 98% by 5 min, held at 98% for 1 min, and then reduced again to 20% in 0.1 min. The
column was equilibrated in 20% solvent B for 3 min between runs.
Triclosan was detected using an AB Sciex API 4000 QTrap mass spectrometer (AB Sciex, Foster City,
CA) running in negative ion electrospray ionization mode (ESI) using a Turbo V ESI ion source. Triclosan
was detected using the instrument settings listed in Table S1 in the supplemental material. A precursor
ion scan was performed for the 35m/z product ion to determine the mass spectrum of triclosan,
13C12-triclosan, and any potential metabolites (Fig. S4a). Because triclosan contains three chlorine atoms,
its mass spectrum includes prominent isotope peaks (M2 and M4) corresponding to the natural
abundance of 37Cl (Fig. S4b). To improve sensitivity, product ions from the two most abundant
isotopologues were detected and added together prior to peak integration. Peaks for triclosan and
internal standard were integrated with Analyst software (AB Sciex) and normalized. Normalized peak
areas varied linearly with triclosan concentration above 1.6 ng/ml.
Pooled urine samples from three to four mice were spiked with 100 ng/ml internal standard and
cleaned as described above. Samples were analyzed by liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS), and triclosan was quantiﬁed using a standard curve (Fig. S4e).
Statistical analysis. Values for the in vitro data are expressed as means  the standard errors of the
mean (SEM) from n 3 replicates. In vitro data were analyzed using a two-tailed Student t test with
statistical signiﬁcance determined when the P value was 0.05. For the mouse data, a Mann-Whitney U
test was used to test for statistical signiﬁcance. Values represent means  the SEM derived from at least
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three independent experiments (*, P 0.05; **, P 0.005; ***, P 0.0005; ****, P 0.00005; ns, difference
not signiﬁcant).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.02312-18.
SUPPLEMENTAL FILE 1, PDF ﬁle, 1 MB.
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